O-Methylbulbocapnine
O-Methylbulbocapnine is an aporphine alkaloid that acts as an inhibitor of LPS-induced inflammatory signaling and a dopamine D1R antagonist. O-Methylbulbocapnine inhibits LPS-induced phosphorylation of p38, ERK1/2, c-Jun, NF-κB p65 at Ser536, and Akt, decreases MyD88 protein levels, and reduces NF-κB nuclear translocation and DNA-binding activity. O-Methylbulbocapnine inhibits LPS-induced production of IL-6, TNF-α, PGE2, and NO, and decreases COX-2 and iNOS expression. O-Methylbulbocapnine can be used for research on Alzheimer's disease, cervical cancer, breast cancer, and malaria.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2490-83-7
- Formel: C20H21NO4
- Molecular Weight:339.39
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Beschreibung
|
p38 |
ERK1 |
ERK2 |
c-Jun |
NF-κB |
p65 |
Akt |
IL-6 |
COX-2 |
TNF-α |
PGE2 |
iNOS |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
70.37 μM
|
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
Antiproliferative activity against human HeLa cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
|
28703314 |
| MDA-MB-231 | IC50 |
56.59 μM
|
Antiproliferative activity against human MDA-MB231 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
Antiproliferative activity against human MDA-MB231 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
|
28703314 |
| MCF7 | IC50 |
39.36 μM
|
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
Antiproliferative activity against human MCF-7 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
|
28703314 |
| 184B5 | IC50 |
73.26 μM
|
Antiproliferative activity against human 184B5 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
Antiproliferative activity against human 184B5 cells assessed as reduction in cell viability incubated for 72 hrs by Sulforhodamine B assay.
|
28703314 |
In Vitro
O-Methylbulbocapnine (OMP) (2.5-15 µg/mL; 2 h pretreatment and 24 h LPS stimulation) inhibits LPS-induced IL-6 production, TNF-α production, and reduces TNF-α production to 42% in RAW264.7 macrophages at 15 µg/mL[1].
O-Methylbulbocapnine (2.5-15 µg/mL; 2 h pre-treatment and 24 h LPS stimulation) inhibits LPS-induced PGE2 production and suppresses COX-2 expression in RAW264.7 macrophages[1].
O-Methylbulbocapnine (2.5-15 µg/mL; 2 h pre-treatment and 24 h LPS stimulation) inhibits LPS-induced iNOS protein expression in RAW264.7 macrophages[1].
O-Methylbulbocapnine (2.5-15 µg/mL; 2 h pre-treatment and 30 min LPS stimulation) inhibits LPS-induced c-Jun translocation and phosphorylation in RAW264.7 macrophages[1].
O-Methylbulbocapnine (2.5-15 µg/mL; 2 h pre-treatment and 30 min LPS stimulation) inhibits LPS-induced phosphorylation of NF-κB p65 at Ser536 in RAW264.7 macrophages, but does not affect IκB-α degradation or p65 nuclear translocation[1].
O-Methylbulbocapnine (2.5-15 µg/mL) inhibits LPS-induced phosphorylation of ERK1/2, p38, and Akt, and decreases MyD88 protein levels in RAW264.7 macrophages[1].
O-Methylbulbocapnine (OMBC) (5-30 µg/mL; 24 h) is cytotoxic to HT1080 human fibrosarcoma cells only at concentrations above 20 µg/mL, thereby establishing a non-toxic dose range below 15 µg/mL[2].
O-Methylbulbocapnine (5-15 µg/mL; 18 h) inhibits HT1080 human fibrosarcoma cell invasion in a dose-dependent manner[2].
O-Methylbulbocapnine (2.5-15 µg/mL; 24 h) decreases uPA secretion from HT1080 human fibrosarcoma cells in a dose-dependent manner[2].
O-Methylbulbocapnine (5-15 µg/mL; 24 h) decreases MT1-MMP expression in HT1080 human fibrosarcoma cells in a dose-dependent manner[2].
O-methylbulbocapnine (72 h) exhibits moderate antiproliferative activity against HeLa, MDA-MB231, MCF-7, and 184B5 cell lines, with IC50 values ranging from 39.36 to 73.26 μM[10].
O-Methylbulbocapnine (0-15 µg/mL; 24 h) reduces the secretion of MMP-9 (IC50 15 µg/mL) and MMP-2 in HT1080 human fibrosarcoma cells in a dose-dependent manner[2].
O-methylbulbocapnine (50 μM; 1 h) acts as a D1R antagonist in HEK293-D1R cells[3].
O-methylbulbocapnine displays relatively low micromolar D1R antagonistic activity in HEK293-D1R cells, with an IC50 of 79.6 μM[3].
O-Methylbulbocapnine (10 µg/mL; 24 h) significantly reduces NF-κB DNA-binding activity in HT1080 human fibrosarcoma cells at a concentration of 10 µg/mL[2].
O-methylbulbocapnine (A2) (0.002-0.01 mg/mL; 24 h) inhibits human proinsulin fibril formation in a dose-dependent manner[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7
-
Concentration:2.5 µg/mL; 5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:2 h (pre-treatment); 24 h (LPS stimulation)
-
Result:Decreased LPS-induced IL-6 production in a dose-dependent manner.
Reduced LPS-induced TNF-α to 42% compared with the control at 15 µg/mL.
-
Cell Line:RAW264.7
-
Concentration:2.5 µg/mL; 5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:2 h (pre-treatment); 24 h (LPS stimulation)
-
Result:Inhibited PGE2 production.
Suppressed the LPS-induced expression of COX-2 in a dose-dependent manner.
-
Cell Line:RAW264.7
-
Concentration:2.5 µg/mL; 5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:2 h (pre-treatment); 24 h (LPS stimulation)
-
Result:Decreased LPS-induced COX-2 expression by more than 50% at 10 µg/mL.
Decreased LPS-stimulated iNOS protein expression in a dose-dependent manner.
Reduced LPS-induced iNOS expression by more than 50% at 5 µg/mL.
-
Cell Line:RAW264.7
-
Concentration:2.5 µg/mL; 5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:2 h (pre-treatment); 30 min (LPS stimulation)
-
Result:Reduced LPS-induced translocation of c-Jun (AP-1) in a dose-dependent manner.
Inhibited LPS-induced phosphorylation of c-Jun.
-
Cell Line:RAW264.7
-
Concentration:2.5 µg/mL; 5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:2 h (pre-treatment); 30 min (LPS stimulation)
-
Result:Did not affect LPS-induced IκB-α degradation.
Did not affect the LPS-induced translocation of p65.
Inhibited the LPS-induced phosphorylation of p65.
-
Cell Line:HT1080 human fibrosarcoma cells
-
Concentration:5 µg/mL; 10 µg/mL; 15 µg/mL; 20 µg/mL; 25 µg/mL; 30 µg/mL
-
Incubation Time:24 h
-
Result:Showed a cytotoxic effect on HT1080 cells at concentrations of more than 20 µg/mL.
Selected a non-toxic dose of less than 15 µg/mL for subsequent experiments.
-
Cell Line:HT1080 human fibrosarcoma cells
-
Concentration:5 µg/mL; 10 µg/mL; 15 µg/mL
-
Incubation Time:18 h
-
Result:Reduced chemo-invasion to 49% at 15 µg/mL.
-
Cell Line:HT1080 human fibrosarcoma cells
-
Concentration:10 µg/mL
-
Incubation Time:24 h
-
Result:Significantly reduced NF-κB DNA binding activity.
Chemical Information
-
CAS. Nr. 2490-83-7
-
Molecular Weight 339.39
-
Formel C20H21NO4
-
SMILES
COC1=C2C3=C(OCO4)C4=CC5=C3[C@](N(CC5)C)([H])CC2=CC=C1OC
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Reinheit & Dokumentation
Verweise
[4]. HY-N21890-3.pdf
[7]. HY-N21890-8.pdf
[8]. Peng CaiYing PC, et al. A new alkaloid from the fruit of Nandina domestica Thunb.
[10]. Le PM, et al. Stephanine from Stephania venosa (Blume) Spreng Showed Effective Antiplasmodial and Anticancer Activities, the Latter by Inducing Apoptosis through the Reverse of Mitotic Exit. Phytotherapy research : PTR. 2017 Sep;31(9):1357-1368. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Keywords
- O-Methylbulbocapnine
- 2490-83-7
- p38 MAPK
- ERK
- NF-κB
- Akt
- MyD88
- Interleukin Related
- TNF Receptor
- PGE synthase
- COX
- NO Synthase
- HEK293-D1R cells
- LPS-induced inflammatory signaling
- HeLa
- Stephania epigaea
- Stephania venosa
- HT1080 human fibrosarcoma cells
- RAW264.7 macrophages
- Nandina domestica
- P. falciparum
- dopamine D1 receptor antagonist
- Inhibitor
- inhibitor
- inhibit